RxDoctor Payments Data

Michael Manoles, MD

Interventional Cardiology · Minneapolis, MNNPI 1578521555

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $196,275 of the $200,582 with a category attached, or 97.9%. Boston Scientific accounts for 98.0% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $38,875, 2.1 times the $18,931 reported in 2019. Among interventional cardiology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$200,582in general payments, 2019–2025

Across 273 payments — averaging $734.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$197K
  • Abbott$1K
  • Merit Medical Systems Inc$802
  • Medtronic$613
  • Teleflex LLC$302
  • Braemar Manufacturing, LLC$248
  • plus $948 from 8 others

What the payments were for

  • Consulting fees$196,27598%
  • Speaking & faculty fees$4160%
  • Travel & lodging$1,4051%
  • Food & beverage$2,4871%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,582 in reported general payments places this provider in the 90th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$84,627
Medicare patients
1,060
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$179,732
EntrestoSacubitril/Valsartan45$48,391
XareltoRivaroxaban42$48,306
JardianceEmpagliflozin36$47,641
FarxigaDapagliflozin Propanediol21$14,844
BrilintaTicagrelor14$14,693
Praluent PenAlirocumab19$9,959
Atorvastatin Calcium285$4,335
Metoprolol Succinate159$4,026
Carvedilol108$1,665
ClopidogrelClopidogrel Bisulfate102$1,554
Lisinopril114$1,356
Isosorbide Mononitrate ErIsosorbide Mononitrate41$1,058
Losartan Potassium64$813
Amlodipine Besylate59$757

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →